The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

Watchful Waiting/Active Sur. Article

Beau2
Beau2 CSN Member Posts: 261 Member
in Prostate Cancer #1
A link to an article on WW/AS. The article did not add a lot of new information on the subject; however, I did find the discussions that followed very interesting.

http://well.blogs.nytimes.com/2012/07/23/choosing-watchful-waiting-for-prostate-cancer/
Like Care

Comments

  • mrspjd
    mrspjd CSN Member Posts: 694 Member
    #2
    AS/M
    What is missing from and not discussed in the article are the parameters for defining which men dx'd with "low risk" PCa (and confirmed by an EXPERT 2nd opinion bx pathology specimen analysis) might be the best candidates for AS/M. Following is info which addresses that and other aspects of Active Surveillance/Monitoring (AS/M):

    http://www.ncbi.nlm.nih.gov/m/pubmed/20800964/
    "Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment."

    "BACKGROUND: With the advent of prostate-specific antigen (PSA) screening and the increase in the number of transrectal ultrasound-guided biopsy cores, there has been a dramatic rise in the incidence of low-risk prostate cancer (LRPC). Because > 97% of men with LRPC are likely to die of something other than prostate cancer, it is critical that patients give thought to whether early curative treatment is the only option at diagnosis."

    "CONCLUSIONS: If guidelines for AS are narrowly defined to include only patients with Gleason 6, tumor volume ≤ 20% in one or two biopsy cores, and PSA levels ≤ 10, few patients are likely to require treatment. Progression-free survival of those treated is likely to be equivalent to patients with similar clinical findings treated at diagnosis."

    Add'l reading:
    http://www.health.harvard.edu/newsweek/When-to-consider-active-surveillance.htm
    http://www.nih.gov/news/health/dec2011/od-07.htm
    Like Care

Discussion Boards